Our lead cancer-selective immunotherapy product is under investigation in a Phase 3 clinical trial, Toca 5, for patients with brain cancer.
Tocagen believes the immune system can be safely activated to fight the patient’s cancer. Driven by this vision, we are developing first-in-class, broadly applicable, product candidates designed to activate a patient’s immune system against their own cancer from within.
Tocagen exists for people with cancer. We are pursuing the discovery, development and commercialization of cancer-selective treatments that can fight cancer while leaving healthy tissue unharmed.
Tocagen is advancing a broadly applicable, cancer-selective gene therapy platform that is designed to deliver therapeutic genes into the DNA of cancer cells and activate a patient’s immune system against their own cancer from within.
Tocagen is committed to fighting cancer. We have multiple clinical trials ongoing with our lead cancer-selective gene therapy product candidate, Toca 511 & Toca FC.
Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly-applicable product candidates designed to activate a patient’s immune system against their own cancer from within.
Tocagen Reports First Quarter 2018 Financial and Business Results
Interested in following our progress? Subscribe below.